Edition:
United Kingdom

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

41.05USD
3:41pm BST
Change (% chg)

$-1.11 (-2.63%)
Prev Close
$42.16
Open
$41.98
Day's High
$42.11
Day's Low
$40.77
Volume
124,641
Avg. Vol
559,109
52-wk High
$44.84
52-wk Low
$14.01

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals Prices Underwritten Public Offering Of 6.25 Mln Shares At $40/Shr
Wednesday, 18 Sep 2019 

Sept 17 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 6.25 MILLION SHARES OF COMMON STOCK AT PRICE TO PUBLIC OF $40.00 PER SHARE.  Full Article

Acadia Pharmaceuticals - Intends To Offer And Sell $250 Million Of Its Common Stock
Tuesday, 17 Sep 2019 

ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - INTENDS TO OFFER AND SELL $250 MILLION OF ITS COMMON STOCK.  Full Article

Acadia Pharmaceuticals Announces Pivotal Phase 3 Harmony Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis
Monday, 9 Sep 2019 

Sept 9 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 HARMONY TRIAL STOPPED EARLY FOR POSITIVE EFFICACY AS PIMAVANSERIN MEETS THE PRIMARY ENDPOINT IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS INC - PHASE 3 HARMONY STUDY MET ITS PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN ACHIEVED ROBUST STATISTICAL SUPERIORITY OVER PLACEBO IN STUDY.ACADIA PHARMA - STUDY TO BE STOPPED EARLY BASED ON PRE-SPECIFIED STOPPING CRITERIA REQUIRING ONE-SIDED P-VALUE LESS THAN 0.0033 ON STUDY'S PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - COMPANY IS PLANNING TO MEET WITH FDA REGARDING A SUPPLEMENTAL NDA SUBMISSION IN 2020.  Full Article

Acadia Pharma Reports Second Quarter Loss Per Share Of $0.38
Wednesday, 31 Jul 2019 

July 31 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.38.Q2 SALES $83.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $72.6 MILLION.SEES FY 2019 SALES $320 MILLION TO $330 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT JUNE 30, 2019, ACADIA'S CASH, CASH EQUIVALENTS, AND INVESTMENT SECURITIES TOTALED $381.9 MILLION.2019 GAAP SG&A GUIDANCE IS INCREASED TO $300 MILLION TO $315 MILLION.  Full Article

Acadia Pharmaceuticals Q1 Loss Per Share $0.59
Wednesday, 1 May 2019 

May 1 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.59.Q1 SALES $63 MILLION VERSUS REFINITIV IBES ESTIMATE OF $60.7 MILLION.SEES FY 2019 SALES $280 MILLION TO $300 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT MARCH 31, 2019, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $414.3 MILLION, COMPARED TO $473.5 MILLION AT DEC 31, 2018.FY2019 REVENUE VIEW $291.2 MILLION -- REFINITIV IBES DATA.  Full Article

Acadia Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Monday, 26 Nov 2018 

Nov 26 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS INC - ACADIA INTENDS TO GRANT UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $30 MILLION OF ITS COMMON STOCK..ACADIA PHARMACEUTICALS INC - INTENDS TO OFFER AND SELL $200 MILLION OF ITS COMMON STOCK.  Full Article

Acadia Pharmaceuticals Reports Third Quarter 2018 Financial Results
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 SALES $58.3 MILLION VERSUS I/B/E/S VIEW $56.3 MILLION.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.58 -- THOMSON REUTERS I/B/E/S.PLAN TO DISCUSS RESULTS OF PHASE 2 CLARITY STUDY EVALUATING PIMAVANSERIN WITH FDA, INITIATE A PHASE 3 PROGRAM IN H1 2019.SEES 2018 NUPLAZID NET SALES GUIDANCE TO BE BETWEEN $220 MILLION AND $225 MILLION.SEES YEAR END 2018 CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES ON ITS BALANCE SHEET TO BE BETWEEN $160 MILLION TO $170 MILLION.  Full Article

Acadia Pharmaceuticals, Neuren Pharmaceuticals Announce Exclusive License Agreement For North American Development, Commercialization Of Trofinetide In Rett Syndrome
Monday, 6 Aug 2018 

Aug 6 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS AND NEUREN PHARMACEUTICALS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR THE NORTH AMERICAN DEVELOPMENT AND COMMERCIALIZATION OF TROFINETIDE IN RETT SYNDROME.ACADIA PHARMACEUTICALS INC - -NEUREN TO RECEIVE US $10 MILLION UPFRONT PLUS POTENTIAL MILESTONES OF UP TO US $455 MILLION AND ROYALTIES.ACADIA PHARMACEUTICALS INC - NEUREN RETAINS ALL RIGHTS TO TROFINETIDE OUTSIDE OF NORTH AMERICA.ACADIA PHARMACEUTICALS - PLANS TO INITIATE PHASE 3 STUDY OF TROFINETIDE FOR TREATMENT OF RETT SYNDROME IN SECOND HALF OF 2019.ACADIA PHARMACEUTICALS - POTENTIAL MILESTONE PAYMENTS TO NEUREN CONSIST OF $105 MILLION SUBJECT TO ACHIEVEMENT OF DEVELOPMENT MILESTONES IN RETT SYNDROME.  Full Article

Acadia Pharma Q4 Loss Per Share $0.55
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Acadia Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.55.QTRLY TOTAL REVENUES $43.6 MILLION VERSUS $12.0 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $44.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Acadia Pharmaceuticals posts Q3 loss of $0.53 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.53.Q3 sales $35.6 million versus I/B/E/S view $32 million.Sees FY 2017 sales $124 million to $127 million.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

UPDATE 1-Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

July 22 Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.